Rivastigmine tartrate and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Rivastigmine tartrate (rivastigmine tartrate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Nuplazid, and have Parkinson's disease.

The phase IV clinical study analyzes which people have Weakness when taking Rivastigmine tartrate. It is created by eHealthMe based on reports of 566 people who have side effects when taking Rivastigmine tartrate from the FDA, and is updated regularly.

What is Rivastigmine tartrate?

Rivastigmine tartrate has active ingredients of rivastigmine tartrate. eHealthMe is studying from 576 Rivastigmine tartrate users. Check the latest studies of Rivastigmine tartrate.

What is Weakness?

Weakness is found to be associated with 3,640 drugs and 6,612 conditions by eHealthMe. Check the latest studies of Weakness.

On Jul, 19, 2026

566 people reported to have side effects when taking Rivastigmine tartrate.
Among them, 46 people (8.13%) have Weakness.

Could Rivastigmine tartrate cause Weakness?

Among these 46 people:

How long have people been on Rivastigmine tartrate when they have Weakness? *

What is the gender of people who have Weakness when taking Rivastigmine tartrate? *

female: 52.27 %
male: 47.73 %

What is the age of people who have Weakness when taking Rivastigmine tartrate? *

What are other drugs people take besides Rivastigmine tartrate? *

What are other side effects people have besides Weakness? *

Hallucinations (sensations that appear real but are created by your mind): 15 people, 32.61%
Malaise (a feeling of general discomfort or uneasiness): 14 people, 30.43%
Memory Loss: 13 people, 28.26%
Tremor (trembling or shaking movements in one or more parts of your body): 13 people, 28.26%
Weight Decreased: 12 people, 26.09%
Fall: 12 people, 26.09%
Fatigue (feeling of tiredness): 12 people, 26.09%
Urinary Tract Infection: 10 people, 21.74%
Parkinson's Disease: 10 people, 21.74%
Hypotension (abnormally low blood pressure): 10 people, 21.74%

What are the existing conditions these people have? *

Parkinson's Disease: 15 people, 32.61%
Dementia Alzheimer's Type (loss of mental ability with alzheimer's symptom): 8 people, 17.39%
High Blood Cholesterol: 7 people, 15.22%
Hallucinations (sensations that appear real but are created by your mind): 7 people, 15.22%
Sleep Disorder: 6 people, 13.04%
Memory Loss: 6 people, 13.04%
Acromegaly (body produces too much growth hormone, leading to excess growth of body tissues): 5 people, 10.87%
Bone Disorder: 5 people, 10.87%
Delusion (a false belief or opinion): 5 people, 10.87%
Agitation (state of anxiety or nervous excitement): 4 people, 8.70%

* Approximation only. Some reports may have incomplete information.

Do you take Rivastigmine tartrate and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rivastigmine tartrate:

Rivastigmine tartrate (576 reports)

Weakness treatments and more:

Weakness (586,876 reports)

Browse all side effects of Rivastigmine tartrate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,640 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,612 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rivastigmine tartrate (the active ingredients of Rivastigmine tartrate) and Rivastigmine tartrate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.